Back to Journals » OncoTargets and Therapy » Volume 14

A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report

Total article views   Abstract views HTML views PDF downloads Totals
707 Dovepress* 691 16+ 86 707
Totals 691 16 86 707
*Since 20 April 2021
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on Google Scholar